Page 93 - 《中国药房》2024年6期

[ 3 ] LIU J L，LIU M，CHAI Z L，et al. Projected rapid growth [15] GAO L，ZHAO F L，LI S C. Cost-utility analysis of lira‐
in diabetes disease burden and economic burden in China： glutide versus glimepiride as add-on to metformin in type
a spatio-temporal study from 2020 to 2030[J]. Lancet Reg 2 diabetes patients in China[J]. Int J Technol Assess
Health West Pac，2023，33：100700. Health Care，2012，28（4）：436-444.
[ 4 ] 《中国老年型糖尿病防治临床指南》编写组. 中国老年2 [16] BERTRAM M Y，LAUER J A，DE JONCHEERE K，et al.
型糖尿病防治临床指南：2022年版[J]. 中国糖尿病杂志， Cost-effectiveness thresholds：pros and cons[J]. Bull
2022，30（1）：2-51. World Health Organ，2016，94（12）：925-930.
Writing Group of Clinical Guidelines for the Prevention [17] LI X，XU Z R，JI L N，et al. Direct medical costs for pa‐
and Treatment of Type 2 Diabetes in the Elderly in China. tients with type 2 diabetes in 16 tertiary hospitals in urban
Clinical guidelines for the prevention and treatment of China：a multicenter prospective cohort study[J]. J Diabe‐
type 2 diabetes in the elderly in China：2022 edition[J]. tes Investig，2019，10（2）：539-551.
Chin J Diabetes，2022，30（1）：2-51. [18] SU W，LI C Y，ZHANG L，et al. Meta-analysis and cost-
[ 5 ] WANG L M，GAO P，ZHANG M，et al. Prevalence and effectiveness analysis of insulin glargine 100 U/mL versus
ethnic pattern of diabetes and prediabetes in China in 2013 insulin degludec for the treatment of type 2 diabetes in
[J]. JAMA，2017，317（24）：2515-2523. China[J]. Diabetes Ther，2019，10（5）：1969-1984.
[ 6 ] ALI M K，BULLARD K M，SAYDAH S，et al. Cardiovas‐ [19] DENG J，GU S Y，SHAO H，et al. Cost-effectiveness
cular and renal burdens of prediabetes in the USA：analy‐ analysis of exenatide twice daily（bid）vs insulin glargine
sis of data from serial cross-sectional surveys，1988-2014 once daily（qd）as add-on therapy in Chinese patients with
[J]. Lancet Diabetes Endocrinol，2018，6（5）：392-403. type 2 diabetes mellitus inadequately controlled by oral
[ 7 ] PAN Y S，CHEN W Q，WANG Y J. Prediabetes and out‐ therapies[J]. J Med Econ，2015，18（11）：974-989.
come of ischemic stroke or transient ischemic attack：a [20] CAI X L，SHI L Z，YANG W J，et al. Cost-effectiveness
systematic review and meta-analysis[J]. J Stroke Cerebro‐ analysis of dapagliflozin treatment versus metformin treat‐
vasc Dis，2019，28（3）：683-692. ment in Chinese population with type 2 diabetes[J]. J Med
[ 8 ] HUANG Y L，CAI X Y，MAI W Y，et al. Association be‐ Econ，2019，22（4）：336-343.
tween prediabetes and risk of cardiovascular disease and [21] HOU X Y，WAN X，WU B. Cost-effectiveness of cana‐
all cause mortality：systematic review and meta-analysis gliflozin versus dapagliflozin added to metformin in pa‐
[J]. BMJ，2016，355：i5953. tients with type 2 diabetes in China[J]. Front Pharmacol，
[ 9 ] MOSENZON O，ALGUWAIHES A，LEON J L A，et al. 2019，10：480.
CAPTURE：a multinational，cross-sectional study of cardio‐ [22] WU B，WAN X，MA J. Cost-effectiveness of prevention
vascular disease prevalence in adults with type 2 diabetes and management of diabetic foot ulcer and amputation in
across 13 countries[J]. Cardiovasc Diabetol，2021，20（1）：154. a health resource-limited setting[J]. J Diabetes，2018，10
[10] 中华医学会糖尿病学分会 . 中国 2 型糖尿病防治指南： （4）：320-327.
2020年版[J]. 国际内分泌代谢杂志，2021，41（5）：482-548. [23] PAN C W，SUN H P，ZHOU H J，et al. Valuing health-
Chinese Medical Association，Diabetes Branch.Guideline related quality of life in type 2 diabetes patients in China
for the prevention and treatment of type 2 diabetes melli‐ [J]. Med Decis Making，2016，36（2）：234-241.
tus in China：2020 edition[J]. Int J Endocrinol Metab， [24] CURRIE C J，MCEWAN P，PETERS J R，et al. The rou‐
2021，41（5）：482-548. tine collation of health outcomes data from hospital
[11] American Diabetes Association. Introduction：standards of treated subjects in the Health Outcomes Data Repository
medical care in diabetes：2022[J]. Diabetes Care，2022，45 （HODaR）：descriptive analysis from the first 20 000 sub‐
（Suppl 1）：S1-S2. jects[J]. Value Health，2005，8（5）：581-590.
[12] XIE Z Y，HU J，GU H Y，et al. Comparison of the efficacy [25] CLARKE P，GRAY A，HOLMAN R. Estimating utility
and safety of 10 glucagon-like peptide-1 receptor agonists values for health states of type 2 diabetic patients using
as add-on to metformin in patients with type 2 diabetes：a the EQ-5D（UKPDS 62）[J]. Med Decis Making，2002，22
systematic review[J]. Front Endocrinol，2023，14：1244432. （4）：340-349.
[13] HAYES A J，LEAL J，GRAY A M，et al. UKPDS out‐ [26] 姚嘉奇，管欣，张瑶，等. 药物经济学概率敏感性分析中
comes model 2：a new version of a model to simulate life‐ 关联参数的处理与实践探讨[J]. 中国药物评价，2019，36
time health outcomes of patients with type 2 diabetes mel‐ （2）：150-155.
litus using data from the 30-year United Kingdom Pro‐ YAO J Q，GUAN X，ZHANG Y，et al. Discussion and
spective Diabetes Study：UKPDS 82[J]. Diabetologia， practice of correlating parameters in sensitivity analysis of phar‐
2013，56（9）：1925-1933. macoeconomics[J]. Chin J Drug Eval，2019，36（2）：150-155.
[14] World Health Organization. The world health report 2002 （收稿日期：2023-11-09 修回日期：2024-03-04）
[J]. Midwifery，2003，19（1）：72-73. （编辑：孙 冰）

中国药房 2024年第35卷第6期 China Pharmacy 2024 Vol. 35 No. 6 · 723 ·